SEC Form 4 · accession 0001209191-15-053888

TETRAPHASE PHARMACEUTICALS INC · TTPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP and CFO

Period of report

Jun 12, 2015

Accepted (ET)

Jun 16, 2015 · 5:11 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001373707

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jun 12, 2015	S	10,000	$41.29	D	69,270	D
Common Stock^F2	Jun 15, 2015	M	7,500	$2.03	A	76,770	D
Common Stock^F2,F3	Jun 15, 2015	S	7,500	$41.67	D	69,270	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F2,F4	$2.03	Jun 15, 2015	M	7,500	D	—	Jun 5, 2022	Common Stock	7,500	19,543	D

F1The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $41.28 to $41.41 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F2The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2015.
F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $40.63 to $42.73 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4This option vests as to 6.25% of the shares on September 6, 2012 and further vests as to 6.25% of the shares at the end of each of successive three-month period thereafter until June 6, 2016.